CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial For ALS
"We are delighted with the FDA's letter, which we believe opens a viable pathway for continued development of arimoclomol for ALS and represents a significant step in its advancement as a potential treatment for this debilitating disease," said CytRx's President and CEO Steven A. Kriegsman. "We are addressing the FDA's letter by formulating a Phase IIb clinical trial protocol that will, among other modifications, include escalating dosing of orally administered arimoclomol up to the 400 milligrams, three times daily as originally planned in the previous protocol. As expected, the FDA letter did not indicate a need for additional animal toxicology studies or other studies prior to the revised protocol submission.
"We expect this positive development to support our pursuit of strategic alternatives, including potential partnerships, for the further development of arimoclomol. We are also continuing to evaluate possible clinical development of arimoclomol for stroke recovery and neuropathy, which were not directly affected by the FDA's prior letter relating to the Phase IIb clinical trial for ALS. Those two major therapeutic markets present additional opportunities for CytRx to create significant value for our stockholders." he added.
Arimoclomol is a molecular chaperone regulator drug candidate that is being considered as a treatment for ALS, stroke recovery and other diseases. Molecular chaperone regulator drugs are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of "molecular chaperones." Molecular chaperones detect proteins that are misfolded, and have the ability to refold those proteins into the appropriate, non-toxic shape.
ALS is a progressive degeneration of the brain and spinal column nerve cells that control the muscles that allow movement. ALS is a common neuromuscular disease, affecting an estimated 120,000 people of all races and ethnic backgrounds worldwide. Over a period of months or years, ALS causes increasing muscle weakness, inability to control movement and problems with speaking, swallowing and breathing. According to the ALS Association more than 5,600 people in the U.S. are diagnosed with ALS annually and an estimated 30,000 Americans have ALS at any given time. According to the National Institute of Neurological Disorders and Stroke, most ALS patients die within three to five years after the onset of symptoms.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Corporation, CytRx. "CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial For ALS." Medical News Today. MediLexicon, Intl., 10 Sep. 2009. Web.
22 Jun. 2017. <http://www.medicalnewstoday.com/releases/163406.php>
Corporation, C. (2009, September 10). "CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial For ALS." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.